Effects of the inhibition of aromatic aminoacids decarboxylase on prolactin secretion in humans.
Carbidopa, at the dose of 250 mg. and benserazide at the dose of 125 mg, given orally in a single dose to healthy women aged between 23 - 26 years enhance significantly serum prolactin. The effect is not shared by two other inhibitors of AADC, namely alpha-methyl DOPA (500 mg) and fentiazac (400 mg). The effect of benserazide is suppressed by bromocriptine (2.5 mg) and blunted by 1-DOPA (400 mg) given orally simultaneusly.
D000328:Adult; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001545:Benserazide / Q000494:pharmacology; D001971:Bromocriptine / Q000494:pharmacology; D002230:Carbidopa / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D005260:Female; D006801:Humans; D011388:Prolactin / Q000097:blood*
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001971:Bromocriptine; D001545:Benserazide; D011388:Prolactin; D002230:Carbidopa; D004298:Dopamine